at neuromuscular junctions that stimulate muscle contraction. After the toxin binds to a receptor, a portion of the molecule enters the nerve cell and blocks neurotransmitter (acetylcholine) release. The toxin fragment acts as a specific zinc-dependent endopeptidase that cleaves one of several proteins of the neuroexocytosis apparatus. The actual substrate is toxin typespecific [2] .
Laboratory Methods
Specimens obtained from the patient during the first 22 days of hospitalization were tested at the Oregon State Public Health Laboratory; all other specimens were tested at the Centers for Disease Control and Prevention (CDC) Botulism Laboratory. Serum, stool, gastric aspirate, and ileostomy fluid specimens were tested for botulinum toxin by the mouse bioassay [3] . Toxin was identified by neutralization tests using monovalent types A, B, and E and polyvalent types A-F diagnostic antitoxins (available from the CDC Biological Reference Reagent Program). All gastrointestinal specimens received by CDC were also cultured for recovery of C. botulinum [3] . Remnants of the patient's foods and empty jars were cultured for C. botulinum.
Botulinum antitoxin in serum was assayed by determining the neutralizing potency of serum for type A and B botulinum toxins in relation to type-specific International Antitoxin Standards, using mouse protection tests [4, 5] . To determine whether antitoxin antibodies were of human or equine origin, some samples were tested with an ELISA, using type A botulinum toxin as the capture antigen and anti-human IgG and anti-horse IgG for detecting antibodies bound to the toxin (unpublished experimental method, CDC). Specificity of the tests for distinguishing between human and equine antitoxins was verified by tests on serum samples from a person actively immunized with pentavalent (A-E) botulinum toxoid and from a patient treated intravenously (iv) with two vials of equine trivalent antitoxin. Samples from the patient in the present report were tested at a dilution of 1:10, except for 2 of insufficient volume, which were tested at 1:40. Results for patient serum samples are expressed as positive (;:;:0.500 absorbance units [AUD or negative «0.500 AU). Serum samples from a person immunized with pentavalent (A-E) botulinum toxoid and from a patient treated iv with two vials of equine-derived types A, B, and E (ABE) antitoxin were used as controls in the ELISAs.
Case Report and Laboratory Findings
A 67-year-old man with long-standing Crohn's disease of the small and large bowel was hospitalized in 1988 with abdominal pain. He lacked an ileocecal valve because his terminal ileum and right colon had each been resected 21 and 18 years earlier, respectively. Earlier in 1988, a barium swallow study had shown stiffness, nodularity, and narrowing in the distal 16 em of small bowel, including the coloenterostomy. He also had a history of erythema nodosum and rectal abscesses. About 6 months before admission, he had had a few occasions of poorly characterized diplopia but had not sought medical attention; there was no history of other bulbar palsies. At the time of admission, he was taking prednisone (2.5 mg daily).
Physical examination was remarkable only for decreased bowel sounds, abdominal distension, and a draining rectal fistula. Examination by a gastroenterologist showed normal extraocular movements; no neurologic abnormalities were noted. Radiographs after a contrast medium (Gastrografin; Bracco Diagnostics, Princeton, NJ) enema performed on admission showed the distal small bowel to be nodular, stiff, and narrowed; the proximal small bowel was grossly distended. The patient was diagnosed with partial small bowel obstruction and treated with cimetidine (300 mg iv every 8 h), prednisolone (5 mg every 6 h), demerol, and doxepin. Acyclovir (400 mg orally every 8 h) was begun on day 3 for herpetic stomatitis.
On hospital day 3, the patient had dysarthria and dyspnea, and a neurologist obtained a history of unreliable gait and decrease in strength over the previous 2 weeks. Examination disclosed extraocular muscle palsies and bilateral facial weakness. The pupillary light reflexes were normal. The tongue protruded slowly in the midline. The gag reflex was not recorded, and the remainder of the cranial nerves were intact. Muscle strength was slightly depressed in the biceps and deltoid but normal elsewhere. The deep tendon reflexes were depressed at the biceps but normal at the triceps and ankles.
Before the neurologic examination could be completed, the patient had respiratory arrest and was immediately resuscitated, intubated, and ventilated. A diagnosis of Guillain-Barre syndrome was made on the basis of an elevated spinal fluid protein level (96 mg/l 00 mL with no cells) on hospital day 6, an equivocal edrophonium (Tensilon; ICN Pharmaceuticals, Costa Mesa, CA) test, and a lack of response to iv neostigmine. (Lumbar puncture was not repeated because the patient began receiving warfarin by nasogastric tube on day 14 because of a history of recurrent venous thromboses and pulmonary embolism.) Sensory complaints were not documented, but examination was limited because the patient was intubated.
Electromyography (EMG) disclosed mild slowing of median and ulnar motor nerve conduction velocity, no conduction block, and normal-amplitude compound muscle action potentials. Although no facilitation of the muscle action potential occurred immediately after maximal exercise for 30 s, rapid repetitive stimulation at high frequency (e.g., 50 Hz) was not done. Over the next few days, the deep tendon reflexes were gradually lost, followed by complete loss of strength. On hospital day 10, the pupils were 3-4 mm and, for the first time, were noted to be minimally reactive to light. Serum and stool specimens for botulism testing were obtained but were not initially tested.
Treatment of the patient's presumptive Guillain-Barre syndrome with plasmapheresis on five occasions resulted in no improvement. Pneumonia developed, which was treated on day 6 with ticarcillin and clavulanate (Timentin [SmithKline Beecham, Philadelphia], 3.1 g iv every 4 h); on day 7, when sputum cultures yielded staphylococci, therapy was changed to nafcillin (2 g iv every 4 h). On day 10, therapy was changed to clindamycin (900 mg iv every 8 h for 9 days) because of suspicion that the pneumonia was also due to anaerobes. Hydrocortisone in doses ranging from 10 to 50 mg (iv every 8 h) was administered until the patient underwent surgery. Total parenteral nutrition was begun on day 8 and continued until after surgery.
During week 2, nasogastric tube outputs ranged from 1.5 to 2.0 L daily. Over the next 3 months, metoclopramide (Reglan; A. H. Robins, Richmond, VA) was administered by nasogastric tube for ileus, but attempts to remove the tube failed because of recurrence of abdominal pain and gastric distension. On at least one occasion, an apparently feculent nasogastric aspirate raised the possibility of a gastrocolic fistula. The patient received cimetidine (300 mg iv every 8 h for 3 days), famotidine (20 mg iv every 12 h for 24 days and later via nasogastric tube for 10 days), and ranitidine (50 mg iv every 8 h for 26 days); during these courses, he also received sucralfate (1 g every 6 h for 78 days). In total, he received acid-suppressing agents on 113 of the first 130 days of hospitalization and none thereafter.
On hospital day 14, the serum sample drawn on day 3 was reported to contain botulinum toxin (table 1) . However, equine botulinum antitoxin was not given because the patient could now move his eyes, fingers, and toes, although he remained quadriparetic and respirator-dependent. In week 4, a serum specimen drawn on day 5 was also reported positive for type A botulinum toxin, and the patient was given two vials of equine trivalent botulinum antitoxin iv. As expected, no immediate improvement in signs or symptoms occurred. That same day, because of suspicion that an obstructed bowel or fistulous tract was colonized by C. botulinum, penicillin (5 X 10 6 U iv daily for 9 days) and tobramycin (200 mg every 12 h for 3 days) were administered. However, in week 4, a colonoscopy to the transverse colon found no evidence of active colitis or fistula. A search of the patient's refrigerator and trash can did not reveal home-canned foods or other foods thought likely to contain botulinum toxin. Remnants of prune juice and syrup and empty jars that had contained herring, olives, and honey consumed by the patient were cultured to determine if they might have served as sources of C. botulinum spores. None yielded toxigenic organisms.
EMG was repeated to evaluate the possibility of botulism. In week 3, stimulation of the right and left ulnar nerves at 24 Hz resulted in no facilitation. However, in week 4, the hypothenar compound muscle action potential to ulnar nerve stimulation increased from 0.46 to 0.85 mV after 10 s of ulnar nerve stimulation at 48 Hz, findings typical for botulism.
In week 4, after consultationwith CDC, a diagnosis of botulism most likely due to intestinal colonization was made. In week 5; antimicrobial therapy was changed to ceftriaxone (2 g iv daily) in an attempt to eradicate C. botulinum and was continued until day 74, when pancytopenia was noted. The first intestinal contents that were cultured were received by the CDC laboratory in week 5; these yielded type A toxin-producing C. botulinum obtained from enema fluid in week 3 and from a fecal swab and a gastric aspirate in week 4. The patient developed Acinetobacter pneumonia and received tobramycin (350 mg iv daily) and aztreonam (2 g iv every 8 h) for 12 days. In week 13, he developed sepsis from a central vein catheter. Blood cultures yielded coagulasenegative Staphylococcus species, Klebsiella oxytoca, and Acinetobacter species. The catheter was removed, and he was treated with vancomycin (1 g iv every 12 h for 4 days) and later with imipenem-cilastatin sodium (Primaxin [Merck, West Point, PA]; 500 mg every 6 h for 2 days).
In total, the patient received antimicrobial agents on 81 of his first 90 hospital days and none thereafter. Over the next few weeks, the patient's strength gradually improved, but he remained quadriparetic and respirator-dependent.
Gastric aspirates obtained between weeks 4 and 18 contained either C. botulinum type A toxin or organisms (or both), again raising the possibility of a gastrocolic or gastroileal fistula. In week 16, a contrast radiographic study via nasogastric tube showed dye reaching the splenic flexure within 30 min, strongly suggesting the presence of a fistula.
A laparotomy in week 19 (hospital day 130) showed that the distal ileum was inflamed, with a stenotic lumen of only 3-4 mm;~1 meter of small bowel was absent due to previous surgery. The colon remaining after the previous surgery was normal. Despite a careful examination of the stomach and small bowel, no fistula was noted. The surgeon resected 19 em of distal ileum and 8 em of colon, and a permanent ileostomy was created. Pathologic examination of the small bowel revealed crypt abscesses and chronic infiltrates extending to the serosa.
Stool specimens obtained the day before and the day of surgery and a specimen of small bowel contents obtained at surgery yielded type A toxin-producing C. botulinum; free toxin was not detected in these specimens. A serum specimen obtained on the day of surgery also did not contain botulinum toxin.
Because of the continued presence of C. botulinum in the gastrointestinal tract and the patient's slow recovery, administration of a second course of equine botulinum antitoxin was anticipated. In preparation for it, on day 130 (week 19), the patient's serum was assayed to determine whether any equine antitoxin remained from the antitoxin administered in week 4. Quite unexpectedly, a high titer of botulinum antitoxin that specifically neutralized type A, but not type B, botulinum toxin was detected by the mouse assay (0.36 IU/mL) (table 1). Even more surprisingly, when subsequently examined by an ELISA that distinguished between equine and human antitoxin antibodies, the antitoxin in the patient's serum was found to be human in origin, that is, a response by his own immune system to exposure to botulinum toxin. This endogenous neutralizing antibody remained detectable at protective levels (>0.02 lUI mL) for > 1 year after it was first detected and reached a maximum of 2.47 IU/mL in week 34 of hospitalization. All 8 sera tested by the mouse neutralization assay against both types A and B botulinum toxin specifically neutralized type A, but not type B, botulinum toxin. The antitoxin antibodies in all 9 serum specimens examined by ELISA were of human, .not equine, origin.
The patient's strength gradually improved. He was removed from the respirator during week 31 and was discharged almost 1 year after admission. He weighed 78 kg, 5 kg less than on admission; his abdominal pain had resolved, and he was able to walk and to live independently.
Discussion
This adult with botulism due to intestinal colonization developed an immune response that was protective for mice; we are not aware of a similar case. Koenig et al. [6, 7] reported that persons who had types Band E foodbome botulism did not have detectable serum antitoxin antibodies and did not develop an anamnestic response after parenteral administration of pentavalent botulinum toxoid. Two patients who experienced second episodes of foodbome botulism due to ingestion of preformed toxin [8, 9] have been described, providing further evidence that antitoxic immunity does not generally develop in patients with foodbome botulism. These observations support an old adage that "the lethal dose of botulinum toxin is less than the antigenic dose." Rubin et aL [10] reported positive ELISA reactions with convalescent-phase serum from 2 infants diagnosed with infant botulism. However, the plates were coated with monovalent type A, B, or E or pentavalent botulinum toxoid, all of which contain an estimated 80% non-toxinderived protein (unpublished data, CDC); the investigators did not determine whether the titer rise represented neutralizing antibodies against the infecting toxin type or, in fact, against any botulinum toxin. However, antibodies can develop against botulinum toxin used to treat torticollis and other conditions, and these have been associated with treatment failure [11] .
Antitoxin was first measured in this patient's serum at 104 days, or 16 half-lives, after administration of equine ABE antitoxin, when the expected residual type A antitoxin would have been <0.0001 IU/mL, below the detectable limit in the bioassay. (Treatment with 2 vials ofABE antitoxin results in a peak serum level of type A antitoxin of~5 IU/mL, with a half-life of 6.5 days [4] .) The fact that subsequent samples showed higher levels of antitoxin, that type B antitoxin (which was present in the equine antiserum) was not detected, and that the antitoxin reacted with anti-human IgG but not with anti-equine IgG provides further confirmation that it was endogenously produced.
Botulism due to intestinal colonization with C. botulinum typically occurs in infants [12] . Nine other confirmed or suspected cases of adult botulism due to intestinal colonization have been reported in some detail [13] [14] [15] [16] [17] [18] [19] .
C. botulinum is rarely, if ever found in the human gastrointestinal tract in culturally demonstrable numbers in the absence of botulism [20, 21] . In this patient, obstruction of the terminal ileum allowed C. botulinum to persist in the small bowel. Whether there was a nidus of C. botulinum infection in the inflamed terminal ileum or simply bowel obstruction with intraluminal colonization is not known. The patient's associated ileus probably permitted colonization, which extended up to the stomach. Clearly the location of the problem was the inflamed small bowel, because the organism disappeared from the stool after resection. Some abnormality in small bowel structure or function, such as jejunoileal bypass for obesity [13] [14] [15] 17] , gastroduodenostomy [14, 16] , or vagotomy and pyloroplasty [18] , was present in at least 5 of the 9 previously reported cases. Another patient had had a colostomy because of bowel cancer [13] .
Multiple courses of antimicrobial agents administered for >60% of the days before surgery probably eradicated competing flora and thus contributed to prolonged colonization. Administration of antimicrobial agents was associated with onset of symptoms in at least 3 other cases of intestinal colonization [14, 16, 19] . Experimentally, resistance of adult mice to colonization with C. botulinum is significantly reduced and clinical botulism can occur when the gut flora is changed by feeding an antimicrobial agent [22] [23] [24] .
Drug-induced achlorhydria from receipt of acid-suppressing agents for > 85% of the days before surgery was probably another contributing factor to colonization. Germination of spores of C. botulinum [25] and growth of the organism [26] are enhanced in a neutral or alkaline environment. Several features of this case initially suggested diagnoses other than botulism, and botulism was considered less likely than other diagnoses because the patient had not eaten a food likely to have contained preformed toxin. Myasthenia gravis was considered because of a recent history of diplopia, and possible improvement with a edrophonium test. Features suggesting Guillain-Barre syndrome included the slow evolution ofthe patient's weakness, slowing of nerve conduction, depression of tendon reflexes before paralysis, and high cerebrospinal fluid protein level. Botulism has been misdiagnosed as Guillain-Barre syndrome in the past [27] .
Botulism in adults caused by intestinal colonization is rare but may occur more commonly than is recognized. It should be considered for patients with descending flaccid paralysis, especially those with a preceding alteration in small bowel function. Features of botulism due to intestinal colonization may be atypical, obscuring the diagnosis. Whether endogenous production of antitoxin antibodies occurs in other persons with intestinal colonization botulism and whether it contributes to recovery are unknown.
